Most of the detected genomic alterations with potential clinical significance in NSCLC were found significantly enriched in younger patient tumors including SNVs in RAD51B, SMARCB1, IDH2, RAD51, CREBBP, LZTR1, IRF4 and fusions with FLI1, while SNVs in RBM10 and DNMT3A were significantly enriched in older patient tumors (Figure 1A; Table 2; Supplementary Tables 2A, 3A). This evidence concerns the gene SMARCB1 and non-small cell lung carcinoma.